AI-ACCELERATED DRUG DISCOVERY
Available from Reaxense
This protein is integrated into the Receptor.AI ecosystem as a prospective target with high therapeutic potential. We performed a comprehensive characterization of Type-1 angiotensin II receptor including:
1. LLM-powered literature research
Our custom-tailored LLM extracted and formalized all relevant information about the protein from a large set of structured and unstructured data sources and stored it in the form of a Knowledge Graph. This comprehensive analysis allowed us to gain insight into Type-1 angiotensin II receptor therapeutic significance, existing small molecule ligands, relevant off-targets, and protein-protein interactions.
Fig. 1. Preliminary target research workflow
2. AI-Driven Conformational Ensemble Generation
Starting from the initial protein structure, we employed advanced AI algorithms to predict alternative functional states of Type-1 angiotensin II receptor, including large-scale conformational changes along "soft" collective coordinates. Through molecular simulations with AI-enhanced sampling and trajectory clustering, we explored the broad conformational space of the protein and identified its representative structures. Utilizing diffusion-based AI models and active learning AutoML, we generated a statistically robust ensemble of equilibrium protein conformations that capture the receptor's full dynamic behavior, providing a robust foundation for accurate structure-based drug design.
Fig. 2. AI-powered molecular dynamics simulations workflow
3. Binding pockets identification and characterization
We employed the AI-based pocket prediction module to discover orthosteric, allosteric, hidden, and cryptic binding pockets on the protein’s surface. Our technique integrates the LLM-driven literature search and structure-aware ensemble-based pocket detection algorithm that utilizes previously established protein dynamics. Tentative pockets are then subject to AI scoring and ranking with simultaneous detection of false positives. In the final step, the AI model assesses the druggability of each pocket enabling a comprehensive selection of the most promising pockets for further targeting.
Fig. 3. AI-based binding pocket detection workflow
4. AI-Powered Virtual Screening
Our ecosystem is equipped to perform AI-driven virtual screening on Type-1 angiotensin II receptor. With access to a vast chemical space and cutting-edge AI docking algorithms, we can rapidly and reliably predict the most promising, novel, diverse, potent, and safe small molecule ligands of Type-1 angiotensin II receptor. This approach allows us to achieve an excellent hit rate and to identify compounds ready for advanced lead discovery and optimization.
Fig. 4. The screening workflow of Receptor.AI
Receptor.AI, in partnership with Reaxense, developed a next-generation technology for on-demand focused library design to enable extensive target exploration.
The focused library for Type-1 angiotensin II receptor includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Type-1 angiotensin II receptor
partner:
Reaxense
upacc:
P30556
UPID:
AGTR1_HUMAN
Alternative names:
AT1AR; AT1BR; Angiotensin II type-1 receptor
Alternative UPACC:
P30556; Q13725; Q8TBK4
Background:
The Type-1 angiotensin II receptor (AT1AR), also known as AT1BR, plays a pivotal role in regulating blood pressure and sodium retention by the kidney. This receptor, upon binding with angiotensin II, activates G-alpha proteins and phospholipase C, leading to increased cytosolic Ca(2+) concentrations and stimulation of protein kinase C. Additionally, AT1AR is implicated in the internalization of the SARS-CoV-2 virus through a complex with ACE2 and the viral spike protein, mediated by dynamin 2-dependent endocytosis.
Therapeutic significance:
Renal tubular dysgenesis, a severe disorder characterized by abnormal renal tubular development leading to perinatal death, is associated with mutations affecting AT1AR. Understanding the role of AT1AR could open doors to potential therapeutic strategies for this condition and other blood pressure-related diseases.
